File: b-be-15-bvw1-fiche-dinformation-destinee-au-public.pdfTrial reference: A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c MelanomaDoc type: Information for the public
